Advertisement

Case Studies

  • Niklas JuthEmail author
  • Christian Munthe
Chapter
  • 1.2k Downloads
Part of the International Library of Ethics, Law, and the New Medicine book series (LIME, volume 51)

Abstract

So far, we have been considering numerous factors that are relevant to answer the main question of this book: what screening programmes are morally justified? As we have seen, this hinges on so many factors that it may be hard to see the full picture. In this chapter, we would like to bring these factors together in order to assess different screening programmes that are implemented or suggested. We will do this by considering four contested (types of) screening programmes. Some of these are already up and running, while others are in development or, at least, seriously contemplated for the future. The number of screening programs up and running in the world are legio. They become even more numerous if we include suggested ones. A selection has to be made in order to make the discussion manageable. But why have we selected these ones? Primarily because they are of current interest, controversial, and telling regarding the general debate on which screening is defensible. Non-invasive prenatal diagnosis (Section 5.1) is the next frontier of prenatal diagnosis. Screening for fragile X (Section 5.2) is, similarly, an instance of the next frontier for neonatal screening, since it is an instance of screening for a disorder for which there are few medical benefits of screening (which is a clear difference from PKU-screening). In this regard, it is a case that illuminates the wider question of which benefits that are relevant for assessing (neonatal) screening programs.

Keywords

Down Syndrome Screening Programme Prenatal Diagnosis Mammography Screening Screen Programme 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Bailey, D.B., Jr., D. Skinner, and S.F. Warren. 2005a. Newborn screening for developmental disabilities: Reframing presumptive benefit. American Journal of Public Health 11:1889–1893.CrossRefGoogle Scholar
  2. Bailey, D.B., Jr., D. Skinner, and K.L. Sparkman. 2005b. Discovering fragile X syndrome: Family experiences and perceptions. Pediatrics 2:407–416.Google Scholar
  3. Bailey, D.B., Jr., D. Skinner, A.M. Davis, I. Whitmarsh, and C. Powell. 2008. Ethical, legal, and social concerns about expanded newborn screening: Fragile X syndrome as a prototype for emerging issues. Pediatrics 3:693–704.CrossRefGoogle Scholar
  4. Baily, M.A., and T.H. Murray. 2008. Ethics, evidence, and cost in newborn screening. Hastings Center Report 3:23–31.CrossRefGoogle Scholar
  5. Beauchamp, T.L., and J.F. Childress. 2001. Principles of biomedical ethics, 5th edition. New York, NY and Oxford: Oxford University Press.Google Scholar
  6. Benn, P.A., and A.R. Chapman. 2010. Ethical challenges in providing noninvasive prenatal diagnosis. Current Opinion in Obstetrics and Gynecology 22:128–134.PubMedCrossRefGoogle Scholar
  7. Chiu, R.W.K., R. Akolekar, Y.W.L. Zheng, T.Y. Leung, H. Sun, K.C.A. Chan, et al. 2011. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: Large scale validity study. BMJ 342:c7401.PubMedCrossRefGoogle Scholar
  8. Connor, M., and M. Ferguson-Smith. 1997. Essential medical genetics. Oxford: Blackwell Science Ltd.Google Scholar
  9. Davis, T.C., S.G. Humiston, C.L. Arnold, J.A. Bocchini Jr., P.F. Bass 3rd, E.M. Kennen, et al. 2006. Recommendations for effective newborn screening communication: Results of focus groups with parents, providers, and experts. Pediatrics 117:326–340.Google Scholar
  10. Dawson, A. 2007. Vaccination ethics. In Principles of health care ethics, eds. R.E. Achcroft, A. Dawson, H. Draper, and J.R. McMillan. Chichester: Wiley.Google Scholar
  11. de Jong, A., W.J. Dondorp, C.E. de Die-Smulders, S.G. Frints, and G.M. de Wert. 2010. Non-invasive prenatal testing: Ethical issues explored. European Journal of Human Genetics 18:272–277.PubMedCrossRefGoogle Scholar
  12. Duffy, S.W., T. László, and R.A. Smith. 2002. The mammography screening trials: Commentary on the recent work by Olson and Götzcshe. Journal of Surgical Oncology 81:159–166 (discussion 162–166).PubMedCrossRefGoogle Scholar
  13. Esserman, L., Y. Shieh, and I. Thompson. 2009. Rethinking screening for breast cancer and prostate cancer. JAMA 302:1685–1692.PubMedCrossRefGoogle Scholar
  14. Fang, F., N.L. Keating, L.A. Mucci, H.O. Adami, M.J. Stampfer, U. Valdimarsdóttir, and K. Fall. 2010. Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis: Cohort study in the United States. Journal of the National Cancer Institute 102(5):307–314.PubMedCrossRefGoogle Scholar
  15. Favre, R., N. Duchange, C. Vayssière, M. Kohler, N. Bouffard, M.C. Hunsinger, et al. 2007. How important is consent in maternal serum screening for Down syndrome in France? Information and consent evaluation in maternal serum screening for Down syndrome: A French study. Prenatal Diagnosis 3:197–205.CrossRefGoogle Scholar
  16. Freedman, D.A., D.B. Petitti, and J.M. Robins. 2004. On the efficacy of screening for breast cancer. International Journal of Epidemiology 33:43–55.PubMedCrossRefGoogle Scholar
  17. Gøtzsche, P.C., and M. Nielsen. 2009. Screening for breast cancer with mammography (review). Copenhagen: The Cochrane Collaboration, Wiley.Google Scholar
  18. Hall, A., A. Bostanci, and C.F. Wright. 2010. Non-invasive prenatal diagnosis using cell-free fetal DNA technology: Applications and implications. Public Health Genomics 13:246–255.PubMedCrossRefGoogle Scholar
  19. Hoffman, R.M. 2010. Randomized trial results did not resolve controversies surrounding prostate cancer screening. Current Opinion in Urology 20:189–193.PubMedCrossRefGoogle Scholar
  20. Hoffman, R.M., M.P. Couper, B.J. Zikmund-Fisher, C.A. Levin, M. McNaughton-Collins, D.L. Helitzer, et al. 2010. Prostate cancer screening decisions: Results from the National Survey of Medical Decisions (DECISIONS study). Archives of Internal Medicine 169:1611–1618.CrossRefGoogle Scholar
  21. Hugosson, J., S. Carlsson, G. Aus, S. Bergdahl, A. Khatami, P. Lodding, et al. 2010. Mortality results from the Göteborg randomized population-based prostate-cancer screening trial. Lancet Oncology 11:725–732.PubMedCrossRefGoogle Scholar
  22. Ilic, D., D. O’Connor, S. Green, and T. Wilt. 2008. Screening for prostate cancer (Review). Copenhagen: The Cochrane Collaboration, Wiley.Google Scholar
  23. Jenssen Hagerman, R., and P.J. Hagerman. (eds.) 2002. Fragile X syndrome: Diagnosis, treatment, and research, 3rd edition. Baltimore, MD: Johns Hopkins University Press.Google Scholar
  24. Juengst, E.T. 2003. Enhancement uses of medical technology. In Encyclopedia of bioethics, 3rd edition, ed. S.G. Post. New York, NY: Macmillan Reference USA.Google Scholar
  25. Juth, N. 2005. Genetic information – values and rights: The morality of presymptomatic genetic testing. Göteborg: Acta Universitatis Gothoburgensis.Google Scholar
  26. Lun, F.M., N.B. Tsui, K.C. Chan, T.Y. Leung, T.K. Lau, P. Charoenkwan, et al. 2008. Noninvasive prenatal diagnosis of monogenic diseases by digital size selection and relative mutation dosage on DNA in maternal plasma. Proceedings of the National Academy of Sciences of the United States of America 50:1990–1995.Google Scholar
  27. McPherson, K. 2010. Should we screen for breast cancer? BMJ 341:233–234.Google Scholar
  28. Munthe, C. 1996. The moral roots of prenatal diagnosis. Ethical aspects of the early introduction and presentation of prenatal diagnosis in Sweden. Göteborg: Centrum för forskningsetik.Google Scholar
  29. Munthe, C. 2008. The goals of public health: An integrated, multidimensional model. Public Health Ethics 1(1):39–53.CrossRefGoogle Scholar
  30. Neal, D.E. 2010. PSA testing for prostate cancer improves survival – but can we do better? The Lancet Oncology 11:702–703.PubMedCrossRefGoogle Scholar
  31. Newschaffer, C.J., K. Otani, M.K. McDonald, and L.T. Penberthy. 2000. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. Journal of the National Cancer Institute 92:613–621.PubMedCrossRefGoogle Scholar
  32. Ravitsky, V. 2009. Non-invasive prenatal diagnosis: An ethical imperative. Nature Reviews Genetics 10:733.PubMedCrossRefGoogle Scholar
  33. Saltvedt, S. 2005. Prenatal diagnosis in routine antenatal care – A randomised controlled trial. Stockholm: Kongl Carolinska Medico Chirurgiska Institutet.Google Scholar
  34. Salwén, H. 2003. Hume’s law: An essay on moral reasoning. Stockholm: Almqvist & Wiksell International.Google Scholar
  35. Schmitz, D., C. Netzer, and W. Henn. 2009. An offer you can't refuse? Ethical implications of non-invasive prenatal diagnosis. Nature Reviews Genetics 10:515.PubMedCrossRefGoogle Scholar
  36. Schröder, F.H., J. Hugosson, M.J. Roobol, T.L. Tammela, S. Ciatto, V. Nelen, et al. 2009. Screening and prostate-cancer mortality in a randomized European study. The New England Journal of Medicine 13:1320–1328.CrossRefGoogle Scholar
  37. Segall, S. 2010. Health, luck, and justice. Princeton, NJ: Princeton University Press.Google Scholar
  38. Skinner, D., K. Sparkman, and D.B. Bailey Jr. 2003. Screening for fragile X syndrome: Patient attitudes and perspectives. Genetics in Medicine 5:378–384.PubMedCrossRefGoogle Scholar
  39. Skrabanek, P. 1985. False premises and false promises of breast cancer screening. The Lancet 326(8446):94–95.CrossRefGoogle Scholar
  40. Skrabanek, P. 2000. False premises, false promises: Selected writings of Peter Skrabanek. Glasgow: Tarragon Press.Google Scholar
  41. Smith, D.S., P.A. Humphrey, and W.J. Catalona. 1997. The early detection of prostate carcinoma with prostate specific antigen: The Washington University experience. Cancer 80:1853–1856.CrossRefGoogle Scholar
  42. van den Heuvel, A., L. Chitty, E. Dormandy, A. Newson, Z. Deans, S. Attwood, S. Haynes, and T.M. Marteau. 2009. Will the introduction of non-invasive prenatal diagnostic testing erode informed choices? An experimental study of health care professionals. Patient Education and Counseling 78:24–28.PubMedCrossRefGoogle Scholar
  43. van der Schoot, C.E., S. Hahn, and L.S. Chitty. 2008. Non-invasive prenatal diagnosis and determination of fetal Rh status. Seminars in Fetal & Neonatal Medicine 13, 63–68.CrossRefGoogle Scholar
  44. Wright, C.F., and H. Burton. 2008. The use of cell-free fetal nucleic acids in maternal blood for non-invasive prenatal diagnosis. Human Reproduction Update1:139–151.CrossRefGoogle Scholar
  45. Zackrisson, S., I. Andersson, L. Janzon, J. Manjer, and J.P. Garne. 2006. Rate of over-diagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: Follow-up study. BMJ 332:689–692.PubMedCrossRefGoogle Scholar
  46. Zamerowski, S.T., M.A. Lumley, R.A. Arreola, K. Dukes, and L. Sullivan. 2001. Favorable attitudes toward testing for chromosomal abnormalities via analysis of fetal cells in maternal blood. Genetics in Medicine 3:301–309.PubMedCrossRefGoogle Scholar
  47. Deans, Z., and A.J. Newson. 2010. Should non-invasiveness change informed consent procedures for prenatal diagnosis? Health Care Analysis, 2010 Mar 9. [Epub ahead of print, doi: 10.1007/s10728-010-0146-8]Google Scholar
  48. Dew-Hughes, D. (ed.) 2003. Educating children with Fragile X syndrome. A multi-professional view. London: Routledge. DnaDirect. Webportal to commercial genetic services. Online access: http://www.dnadirect.com/web/consumers. Last accessed 29 Oct 2010.
  49. Justman, S. 2010. Uninformed consent: Mass screening for prostate cancer. Bioethics, Article first published online: 28 Jun 2010, doi: 10.1111/j.1467-8519.2010.01826.x.Google Scholar
  50. Malmqvist, E., G. Helgesson, J. Lehtinen, K. Natunen, and M. Lehtinen. 2010. The ethics of implementing human papillomavirus vaccination in developed countries. Medicine, Health Care, and Philosophy, 19 Sep 2010. [Epub ahead of print] PMID: 20853152 [PubMed – as supplied by publisher]Google Scholar
  51. March, J.G., and J.P. Olsen. 1989. Rediscovering institutions: The organizational basis of politics. New York, NY: Free Press.Google Scholar
  52. Renner, I. (ed.) 2006. Experience of pregnancy and prenatal diagnosis. Bundeszentrale für gesundheitliche Aufklärung [online] http://www.bzga.de/?uid=25d093aacb9296ea646b087b68c27996&id=medien%26sid=88%26idx=1496. Accessed Nov 2010.
  53. U.S. Preventive Services Task Force. 2008. Screening for prostate cancer: US. Preventive Services Task Force recommendation statement. Annals of Internal Medicine 149:185–191.Google Scholar
  54. World Medical Association. 1964–2008. Declaration of Helsinki: Ethical principles for medical research involving human subjects. Available online: http://www.wma.net/en/30publications/10policies/b3/17c.pdf. Accessed 25 Oct 2010.
  55. Swedish Organized Service Screening Evaluation Group. 2006. Reduction in breast cancer mortality from organized service screening with mammography. Further confirmation with extended data. Cancer Epidemiology, Biomarkers and Prevention 15:45–51.CrossRefGoogle Scholar
  56. Törnberg, S., and L. Nyström. 2009a. Skrämselpropaganda om mammografi (Propaganda with intention to scare regarding mammography). Läkartidningen 42:2664–2665.Google Scholar
  57. Törnberg, S., and L. Nyström. 2009b. Värre med utredningsorsakad oro än förtidig död i bröstcancer? (Is it worse with examination-induced anxiety than premature death in cancer?). Läkartidningen 45:3018.Google Scholar
  58. Gøtzsche, P.C., and K.J. Jörgensen. 2009a. Ärlig information om mammografiscreening, tack! (Honest information about mammography screening, please!). Läkartidningen 44:2860–2861.Google Scholar
  59. Gøtzsche, P.C., and K.J. Jörgensen. 2009b. Överdiagnostik vid mammografiscreening är ett allvarligt problem (Overdiagnosis in mammography screening is a serious poblem). Läkartidningen 47:3180.Google Scholar
  60. Domenighetti, G., B. D’Avanzo, M. Egger, F. Berrino, T. Perneger, P. Mosconi, et al. 2003. Women’s perception of the benefits of mammography screening: Population-based survey in four countries. International Journal of Epidemiology 32:816–821.PubMedCrossRefGoogle Scholar
  61. Wright, C.F., and L.S. Chitty. 2009. Cell-free fetal DNA and RNA in maternal blood: Implications for safer antenatal testing. BMJ 339:b2451. doi: 10.1136/bmj.b2451.Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  1. 1.Karolinska Institutet Dept. Learning, Informatics, Management & Ethics (LIME)StockholmSweden
  2. 2.Dept. Philosophy, Linguistics & Theory of ScienceUniversity of GöteborgGöteborgSweden

Personalised recommendations